FDA Panels Back Black Box Warning on Antidepressants: Analysis of 24 Pediatric Trials Showed an Increased Suicidality Risk of 2%-3%

By Mechcatie, Elizabeth | Clinical Psychiatry News, October 2004 | Go to article overview

FDA Panels Back Black Box Warning on Antidepressants: Analysis of 24 Pediatric Trials Showed an Increased Suicidality Risk of 2%-3%


Mechcatie, Elizabeth, Clinical Psychiatry News


BETHESDA, MD. -- A black box warning alerting prescribers to the risk of suicidal behavior and ideation with antidepressants in pediatric patients will likely be added to the labels of antidepressants, as recommended by the majority of the members of two Food and Drug Administration advisory panels.

At the end of a widely anticipated 2-day joint meeting, the FDA's psychopharmacologic drugs and pediatric advisory committees concluded that a reanalysis of the suicidality data from 23 pediatric trials of antidepressants, and a recently published trial of fluoxetine, indicated that those drugs were associated with an increased risk of suicidality--a term defined by the FDA as suicidal behavior and ideation.

An FDA analysis of 24 clinical trials determined that the increased risk over placebo was about 2%-3%, which, despite the limitations of the studies, was described as a "reasonably consistent signal for risk" by Dr. Thomas Laughren, leader of the FDA's psychiatric drug products group.

The relative risks of nine newer antidepressants in the trials--citalopram (Celexa), fluvoxamine (Luvox), paroxetine (Paxil), fluoxetine (Prozac), sertraline (Zoloft), venlafaxine (Effexor XR), mirtazapine (Remeron), nefazodone (Serzone), and bupropion (Wellbutrin)--varied, and most of the risks came from but were not limited to trials of major depressive disorder (MDD).

The panels agreed that it was better not to specify a chemical class of antidepressants, but antidepressants as a class. They also opted not to specify one disorder, since there was an increased risk detected in non-MDD trials of some of the drugs.

Panel members then voted 15-8 in favor of adding a black box warning to convey this information to prescribers. Dr. Robert Temple, director of the FDA's Office of Drug Evaluation I, Rockville, Md., said that a black box--the strongest drug warning available, which always appears at the top of a label--was used for information the FDA wants everybody to pay attention to and that it was "particularly attractive when you can do something about it."

The FDA usually follows the recommendations of its panels, which are not binding. At a press conference immediately after the meeting. Dr. Temple said the FDA would try to come up with changes "relatively quickly" but that this process could take several months.

He could not say whether the FDA would adopt the black box warning, but he added that the new warning would emphasize that at least in pediatric patients, there is evidence that the drugs themselves increase the risk of suicidality, as panel members concluded.

Dr. Joan Chesney, chair of the pediatric drugs panel, said she was struck again by the public testimonies, as she had been at the February meeting, that many of those who committed suicide had never expressed suicidal ideation, yet had proceeded to commit suicide during treatment.

Although such a warning would make prescribing more difficult and might alarm parents, it is "worth that complication because it will raise the threshold for prescribing and force engagement in a discussion not only about the risks but the potential benefits of alternatives to medications," said Dr. Wayne Goodman, chair of the psychopharmacologic drugs panel and chair of the department of psychiatry at the University of Florida, Gainesville.

Even though there are limitations to the data, even when considered in aggregate, "it would be premature to identify a particular drug that should be exempted from this warning," Dr. Goodman added. Doing so "could have the unintended consequence of steering traffic" toward prescribing that drug before having sufficient information about the true risk. This would also apply to newly approved antidepressants, the panels agreed. The panels also expressed concern that the warnings would drive physicians toward older tricyclic drugs. But the FDA is planning to add the same warning to those drugs as well. …

The rest of this article is only available to active members of Questia

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

FDA Panels Back Black Box Warning on Antidepressants: Analysis of 24 Pediatric Trials Showed an Increased Suicidality Risk of 2%-3%
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Help
Full screen

matching results for page

    Questia reader help

    How to highlight and cite specific passages

    1. Click or tap the first word you want to select.
    2. Click or tap the last word you want to select, and you’ll see everything in between get selected.
    3. You’ll then get a menu of options like creating a highlight or a citation from that passage of text.

    OK, got it!

    Cited passage

    Style
    Citations are available only to our active members.
    Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

    1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

    Cited passage

    Thanks for trying Questia!

    Please continue trying out our research tools, but please note, full functionality is available only to our active members.

    Your work will be lost once you leave this Web page.

    Buy instant access to save your work.

    Already a member? Log in now.

    Author Advanced search

    Oops!

    An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.